Finasteride and minoxidil hit hair loss from opposite ends — one stops miniaturization, the other forces regrowth. Here's how to tell which the scalp actually needs, and when stacking beats running either alone.
Finasteride and minoxidil get lumped together as "the two FDA drugs" so often that the actual decision — which one, in what order, at what dose — gets glossed over. They are not interchangeable. One is a DHT lever pulled systemically (or topically, with caveats); the other is a vasodilator-slash-follicular-stimulant that does nothing about the underlying androgenic miniaturization. Treating them as a binary choice misses the point. The real question is which mechanism the scalp in front of the mirror actually needs, and whether running both is worth the additional friction.
Finasteride is a 5-alpha reductase type II inhibitor. Standard 1mg oral dosing knocks scalp DHT down roughly 60-70% and serum DHT around the same. Less DHT at the follicle means the miniaturization signal that drives androgenetic alopecia gets quieter. It is a defensive drug: it preserves what is still there and lets borderline-miniaturized follicles recover terminal status over 6-12 months. It does very little for follicles that have fully cycled into dormancy.
Minoxidil is mechanistically messier. It is an ATP-sensitive potassium channel opener, a vasodilator, and — crucially, via sulfotransferase activity in the scalp — a direct stimulator of the anagen phase. It pushes follicles into and through active growth, shortens telogen, and thickens existing hairs. It is an offensive drug: it grows hair, including hair on scalps where the underlying androgen problem is still active.
The Arca et al. comparison (2004) put both head to head in mild-to-severe AGA and concluded both were effective and safe, with oral finasteride more effective overall. That phrasing matters: more effective on average, not categorically better for every responder.
The "both work" framing collapses real differences in responder profile. A more useful breakdown:
The two drugs run on different clocks, and adherence patterns diverge accordingly.
| Oral finasteride 1mg | Topical minoxidil 5% | |
|---|---|---|
| First visible change | 3-4 months (reduced shedding) | 8-16 weeks (dread shed, then regrowth) |
| Peak effect | 12-18 months | 12 months |
| Daily friction | One pill | Twice-daily application, dry time, residue |
| Discontinuation reversal | 6-12 months to baseline | 3-6 months to baseline |
Minoxidil's adherence problem is real and underrated. Twice-daily topical application with dry time before bed is the single biggest reason protocols fail in the wild — not the drug, the routine. This is why oral minoxidil at 1.25-2.5mg has eaten so much market share in the last few years: same mechanism, no scalp residue, one pill, and dose-dependent regrowth that often beats topical 5% on adherence-adjusted outcomes. The trade-off is systemic vasodilation (mild ankle edema, occasional palpitations, hypertrichosis on the face and forearms in a meaningful minority of users).
Finasteride has the opposite problem: trivial adherence, but the sides discussion lives rent-free in every forum thread. Realistically, persistent sexual side effects occur in a small but non-zero percentage of users; most resolve on discontinuation, a minority do not. The harm-reduction move is to start at 1mg every other day or 0.5mg daily for the first 8-12 weeks, gauge tolerance, then titrate. Topical finasteride is a legitimate alternative for users who want the DHT suppression without the same systemic exposure profile — scalp DHT reduction is comparable, serum DHT suppression is partial.
A common refrain on the hairloss subs: "fin holds the line, minox grows it back." Reductive, but directionally correct for most responder profiles.
The practical decision tree most experienced users converge on:
Sequential monotherapy — fin first, minoxidil only if fin underdelivers — is defensible for users who want minimal complexity and are mainly defending existing density. Stacked from the start is the higher-ceiling play for users who need visible regrowth, particularly in the frontal zone.
Oral 5-AR inhibitors meaningfully reduce semen parameters in a subset of users; anyone planning conception in the next 6-12 months should pause oral finasteride and lean on topical fin or dutasteride plus minoxidil instead. Finasteride is also teratogenic — handling of crushed tablets near anyone who could become pregnant is a hard no. Minoxidil's cardiovascular profile is benign at topical doses and mostly benign at low oral doses, but pre-existing untreated hypertension or tachyarrhythmia warrants getting those handled before adding oral minox to the mix.
Finasteride defends, minoxidil regrows, and the question of which to run is really a question of what the scalp needs and how much friction the routine can absorb. For most users with active miniaturization and density still worth saving, oral finasteride alone for the first three months — then layered minoxidil — is the cleanest sequencing. Frontal recession, AAS users, and anyone optimizing for ceiling rather than simplicity should plan on the stack from the start, with microneedling and topical AR antagonists held in reserve for the partial responders at the 9-month mark.
Powered by BTST